Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Wista Laboratories Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 3 art units, indicating distinct examiner assignments with some art-unit overlap.
PALLAY, MICHAEL B is the busiest examiner, with 1 pending matter. Since the busiest examiner does not account for multiple listed actions, counsel should use matter-specific analysis while also checking whether the shared art-unit structure produces recurring technical or claim issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.8% | +33.8% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849744 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | AGGARWAL, SAHIL CHANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19063699 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | PALLAY, MICHAEL B | — |
| 18869709 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | KUCKLA, ANNA GRACE | — |
| 18760513 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1629 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19063699 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | PALLAY, MICHAEL B | 1617 | §103Other | Non-Final OA | — | Pending | Feb 26, 2025 |
| 18869709 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | KUCKLA, ANNA GRACE | 1629 | §103§112DP | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18849744 | METHYLENE BLUE CONTAINING COMPOUNDS FOR THE TREATMENT OF METHAEMOGLOBINAEMIA | AGGARWAL, SAHIL CHANDER | — | §103§112Other | Non-Final OA | — | Pending | Sep 23, 2024 |
| 18760513 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE | PALENIK, JEFFREY T | 1615 | §112DP | Non-Final OA | — | Pending | Jul 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWista Laboratories Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Michael B Pallay has the most, with 1 of Wista Laboratories Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
